BioCentury

8:00 AM GMT, Dec 12, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Strategy

Btk to the future

Johnson & Johnson says the science and first-mover advantage behind Pharmacyclics Inc.'s Btk inhibitor were interesting enough for the pharma to step outside its focus on the tumor microenvironment - and to justify a $150 million upfront payment. The partners, which will share costs and profits, plan to start Phase III testing of PCI-32765 for B cell malignancies in mid-2012.

J&J has spent several years retooling its oncology R&D organization to focus on projects that disrupt the tumor microenvironment. This initiative has involved in-house changes like adding biomarker and translational medicine groups, and bringing in external assets, such as prostate cancer drug Zytiga abiraterone (see BioCentury, Aug. 30, 2010).

However, the pharma

Read the full 1119 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.